(Total Views: 637)
Posted On: 08/17/2020 4:44:20 PM
Post# of 145248
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Ok, so assuming that the FDA doesn't grant an EUA for the M2M population but requires Cytodyn to conduct a Phase 3 trial. What would that look like? Just change the N trial size by what, maybe 20 or 30 patients? Change the "primary" end point to NEWS2? In my mind, it's just a repeat of the Phase 2 trial with highly similar results, no?? It'll just be time wasted and with it, more lives affected.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)